Application of AngioJet thrombus aspiration device for treatment of acute iliofemoral vein thrombosis

The aim of this study was to investigate the efficacy and safety of the AngioJet mechanical thrombus aspiration device for treatment of acute iliofemoral vein thrombosis. A total of 50 patients with iliofemoral vein thrombosis were randomly divided into control and observation groups. For the control group, the catheter was implanted, along with the guidewire and retained. This was followed by urokinase injections. For the observation group, urokinase was sprayed within the thrombus, which was then aspirated. Thrombolytic catheters were retained for 0-3 days. Compared with the control group, thrombolysis times, urokinase dosage, and hospitalization times were significantly reduced in the observation group. For the control group, angiographies after CDT indicated 10, 9, and 6 cases of grade III, II, and I thrombus clearance, respectively. A total of 9 patients exhibited iliac vein occlusion. They were subjected to balloon dilatation and stent implantation. Inferior vena cava filters were removed from 22 cases. For the observation group, patients received thrombus aspiration treatment, followed by 0-3 days of thrombolytic therapy. There were 18, 6, and 1 cases of grade III, II, and I thrombus clearance, respectively. No recurrence was observed during the follow-up period. Blood flow in patients with stents was patent. The AngioJet mechanical thrombus aspiration device is safe and effective in treating acute iliofemoral vein thrombosis. Compared with simple CDT, PMT, combined with low-dose CDT, significantly elevates thrombus clearing efficacy, reduces thrombolytic agent dosage, reduces thrombolytic times, shortens hospitalization times, decreases bleeding, and enhances patient tolerance.